• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020.

出版信息

Ophthalmologe. 2021 Jan;118(Suppl 1):68-77. doi: 10.1007/s00347-020-01250-y.

DOI:10.1007/s00347-020-01250-y
PMID:33146773
Abstract
摘要

相似文献

1
Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020.德国眼科学会、德国视网膜学会和德国眼科医生专业协会关于早产儿视网膜病变抗VEGF治疗的声明：发布时间：2020年5月18日。
Ophthalmologe. 2021 Jan;118(Suppl 1):68-77. doi: 10.1007/s00347-020-01250-y.
2
[Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020].[德国眼科学会、德国视网膜学会和德国眼科医生专业协会关于早产儿视网膜病变抗VEGF治疗的声明：发布时间：2020年5月18日]
Ophthalmologe. 2020 Sep;117(9):873-885. doi: 10.1007/s00347-020-01170-x.
3
Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020.德国眼科学会（DOG）、德国视网膜学会（GRS）和德国眼科医生专业协会（BVA）关于新生血管性年龄相关性黄斑变性抗VEGF治疗的声明：2020年2月状况
Ophthalmologe. 2021 Jan;118(Suppl 1):31-39. doi: 10.1007/s00347-020-01188-1.
4
[Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration - Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the German Professional Asscociation of Ophthalmologists (BVA). Stand 15.10.2022].[新生血管性年龄相关性黄斑变性的抗VEGF治疗——德国眼科学会（DOG）、德国视网膜学会（RG）和德国眼科医生专业协会（BVA）声明。2022年10月15日]
Klin Monbl Augenheilkd. 2023 Feb;240(2):180-189. doi: 10.1055/a-1998-8890. Epub 2023 Feb 22.
5
[Supplementary Statement on IVOM Drugs for the Treatment of Diabetic Macular Edema with Foveal Involvement - Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the German Professional Association of Ophthalmologists (BVA). Status 28 October 2022].[关于治疗累及黄斑中心凹的糖尿病性黄斑水肿的玻璃体内注射药物补充声明——德国眼科学会（DOG）、德国视网膜协会（RG）和德国眼科医生专业协会（BVA）声明。2022年10月28日状况]
Klin Monbl Augenheilkd. 2023 Mar;240(3):327-331. doi: 10.1055/a-2009-5833. Epub 2023 Mar 28.
6
Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.德国眼科学会、德国视网膜学会和德国眼科医生专业协会关于糖尿病性黄斑水肿治疗的声明：日期为2019年8月。
Ophthalmologe. 2021 Jan;118(Suppl 1):40-67. doi: 10.1007/s00347-020-01244-w.
7
[Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the Professional Association of German Ophthalmologists (BVA) on the therapeutic use of voretigene neparvovec-rzyl (Luxturna™) in ophthalmology : Situation January 2019].[德国眼科学会（DOG）、德国视网膜学会（RG）和德国眼科医生专业协会（BVA）关于眼科中使用voretigene neparvovec-rzyl（Luxturna™）进行治疗的声明：2019年1月的情况]
Ophthalmologe. 2019 Jun;116(6):524-533. doi: 10.1007/s00347-019-0885-3.
8
[Supplementary statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on treatment of proliferative diabetic retinopathy : Status November 2019].[德国眼科学会（DOG）、视网膜病学会（RG）和德国眼科医生专业协会（BVA）关于增殖性糖尿病视网膜病变治疗的补充声明：2019年11月状况]
Ophthalmologe. 2020 Aug;117(8):755-759. doi: 10.1007/s00347-020-01116-3.
9
[Statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020].[德国眼科学会（DOG）、视网膜病学会（RG）和德国眼科医生专业协会（BVA）关于新生血管性年龄相关性黄斑变性抗VEGF治疗的声明：2020年2月状况]
Ophthalmologe. 2020 Aug;117(8):746-754. doi: 10.1007/s00347-020-01117-2.
10
[Statement on "Cuba Treatment" of Tapetoretinal Degeneration (retinitis pigmentosa) - Statement of the German Society of Ophthalmology, the German Professional Association of Ophthalmologists, the German Retina Society and the Working Group on Clinical Issues of the Pro Retina Deutschland e. V., status November 2022].
Klin Monbl Augenheilkd. 2023 Apr;240(4):613-614. doi: 10.1055/a-2029-0761. Epub 2023 Apr 25.

引用本文的文献

1
Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity.激光与抗血管内皮生长因子：治疗性早产儿视网膜病变的范式转变
Ophthalmol Ther. 2023 Oct;12(5):2241-2252. doi: 10.1007/s40123-023-00744-7. Epub 2023 Jun 19.

本文引用的文献

1
Using Adult Drug Efficacy Data to Aid in Interpretation of Underpowered Pediatric Studies.
JAMA Ophthalmol. 2021 Feb 1;139(2):217-218. doi: 10.1001/jamaophthalmol.2020.5557.
2
[Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab].[玻璃体内单次注射0.312毫克贝伐单抗后荧光血管造影辅助治疗侵袭性早产儿视网膜病变（APROP）复发]
Klin Monbl Augenheilkd. 2020 Dec;237(12):1468-1476. doi: 10.1055/a-1012-1999. Epub 2019 Nov 26.
3
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.雷珠单抗与激光治疗用于治疗极低出生体重早产儿视网膜病变（RAINBOW）：一项开放标签随机对照试验。
Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12.
4
[Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry].[德国早产儿视网膜病变的治疗病例：来自Retina.net视网膜病变登记处的5年数据]
Ophthalmologe. 2018 Jun;115(6):476-488. doi: 10.1007/s00347-018-0701-5.
5
[Screening for retinopathy of prematurity: Trends over the past 5 years in two German university hospitals].[早产儿视网膜病变筛查：德国两家大学医院过去5年的趋势]
Ophthalmologe. 2018 Jun;115(6):469-475. doi: 10.1007/s00347-018-0675-3.
6
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.比较不同雷珠单抗剂量治疗早产儿视网膜病变的安全性和有效性：一项随机临床试验。
JAMA Pediatr. 2018 Mar 1;172(3):278-286. doi: 10.1001/jamapediatrics.2017.4838.
7
Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.玻璃体内注射阿柏西普对早产儿视网膜病变婴儿全身血管内皮生长因子水平的影响
Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):479-487. doi: 10.1007/s00417-017-3878-4. Epub 2017 Dec 30.
8
Thoracic osteomyelitis and epidural abscess formation due to cat scratch disease: case report.猫抓病所致胸椎骨髓炎及硬膜外脓肿形成：病例报告
J Neurosurg Pediatr. 2016 Dec;25(6):713-716. doi: 10.3171/2016.7.PEDS1677. Epub 2016 Sep 23.
9
Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.玻璃体内注射贝伐单抗单药治疗后复发性早产儿视网膜病变的临床管理
Ophthalmology. 2016 Sep;123(9):1845-55. doi: 10.1016/j.ophtha.2016.04.028. Epub 2016 May 27.
10
Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment.早产儿视网膜病变及贝伐单抗治疗婴儿的神经发育结局
PLoS One. 2016 Jan 27;11(1):e0148019. doi: 10.1371/journal.pone.0148019. eCollection 2016.